NASDAQ:CLVS
Delisted
Clovis Oncology Stock News
$0.151
+0 (+0%)
At Close: Apr 19, 2023
$41.80 Million in Sales Expected for Clovis Oncology (NASDAQ:CLVS) This Quarter
07:28am, Friday, 24'th Apr 2020
Equities analysts predict that Clovis Oncology (NASDAQ:CLVS) will announce $41.80 million in sales for the current quarter, according to Zacks Investment Research. Four analysts have provided estimate
Clovis Oncology (NASDAQ:CLVS) Stock Rating Upgraded by BidaskClub
10:16am, Thursday, 23'rd Apr 2020
Clovis Oncology (NASDAQ:CLVS) was upgraded by analysts at BidaskClub from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, BidAskClub reports
Clovis Oncology Option Alert: May 8 $12.5 Calls Sweep (5) near the Ask: 300 @ $0.35 vs 69 OI; Earnings 5/5 After Close Ref=$9.47
12:00am, Thursday, 23'rd Apr 2020Are Options Traders Betting on a Big Move in Clovis Oncology (CLVS) Stock?
01:00pm, Wednesday, 22'nd Apr 2020
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Clovis Oncology (CLVS) Stock?
01:00pm, Wednesday, 22'nd Apr 2020
Investors need to pay close attention to Clovis Oncology (CLVS) stock based on the movements in the options market lately.
Royal Bank of Canada Reiterates Buy Rating for Clovis Oncology (NASDAQ:CLVS)
07:54am, Wednesday, 22'nd Apr 2020
Clovis Oncology (NASDAQ:CLVS)‘s stock had its “buy” rating reissued by investment analysts at Royal Bank of Canada in a research note issued on Monday, AnalystRatings.com reports. They presently
Are Options Traders Betting on a Big Move in Clovis Oncology (CLVS) Stock?
12:00am, Wednesday, 22'nd Apr 2020Clovis Oncology to Announce First Quarter 2020 Financial Results and Host Webcast Conference Call on May 5
08:05pm, Tuesday, 21'st Apr 2020
Clovis Oncology, Inc. (NASDAQ: CLVS) will announce its first quarter 2020 financial results on Tuesday, May 5, 2020, after the close of the U.S. financial markets. Clovis’ senior management will hos
Clovis Oncology: An Undervalued Diamond In The Rough
01:25pm, Tuesday, 21'st Apr 2020
Clovis’ shares are undervalued for the potential of Rubraca, Lucitanib and FAP. Multiple studies underway of combinations of Bristol-Myers Squibb’s Opdivo (nivo
Arch Oncology Appoints Biotechnology Industry Veteran Julie Hambleton, M.D. to Board of Directors
01:00pm, Tuesday, 21'st Apr 2020
Arch Oncology, Inc., a clinical-stage immuno-oncology company focused on the discovery and development of best-in-class anti-CD47 antibody therapies, today announced the appointment of Julie Hambleton
Ladenburg Thalmann Financial Services Inc. Buys 5,703 Shares of Clovis Oncology (NASDAQ:CLVS)
11:34am, Tuesday, 21'st Apr 2020
Ladenburg Thalmann Financial Services Inc. raised its stake in Clovis Oncology (NASDAQ:CLVS) by 118.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the S
Bank of New York Mellon Corp Lowers Position in Clovis Oncology (NASDAQ:CLVS)
09:00am, Tuesday, 21'st Apr 2020
Bank of New York Mellon Corp lowered its stake in shares of Clovis Oncology (NASDAQ:CLVS) by 55.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities
Clovis Oncology (NASDAQ:CLVS) Stock Rating Lowered by Bank of America
07:06am, Tuesday, 21'st Apr 2020
Clovis Oncology (NASDAQ:CLVS) was downgraded by investment analysts at Bank of America from a “neutral” rating to an “underperform” rating in a report released on Sunday, Benzinga reports. CLV
Why Clovis Oncology, Immunomedics, and Puma Biotechnology All Spiked Today
10:00pm, Monday, 20'th Apr 2020
Investors piled into cancer stocks. Here's why.
